Skip to main content

Global Axial Spondyloarthritis Market is Expected to Grow at Significant CAGR 13.44 During the Forecast Period, 2022-2032

 The ankylosing spondylitis and other members of the spondyloarthritis (SpA) family were considered variations of rheumatoid arthritis (RA) up until the early 1960s. As a result, SpA and RA were initially considered to be separate illnesses, but soon after they were found to be inter-connected due to clinical, laboratory, and imaging features. For the last two decades, axial spondyloarthritis (axSpA) has been the subject of major advances in understanding the disease. Additionally, over the years, the distinction between axial and peripheral SpA as well as the connections between non-radiographic and radiographic axSpA has been formalized. In 2009, the term "axial spondyloarthritis" was introduced to describe a diverse disease family that shares clinical and genetic features, such as involvement of the axial skeleton. The following figure shows the evolution of axSpA over the years. The landscape of axial spondyloarthritis is massively growing, with many emerging and legacy companies venturing into the industry with their respective therapeutic portfolio exclusively developed and designed for the treatment of axial spondyloarthritis (axSpA) such as ankylosing spondylitis and non-radiographic axial spondyloarthritis. Additionally, axSpA is associated with several co-morbidities and extra-articular manifestations such as cardiovascular risk, inflammatory bowel disease, and uveitis. Through imaging, genetic, and biomarker studies, researchers are gaining deeper understanding of the biology of axSpA, which will likely resolve many current problems in axSpA diagnosis and classification. Though there is no cure for axSpA, but there are emerging therapies in the global axial spondylopathies market that improves the symptoms, signs, and quality of life in patients with axSpA.

The current study aims to assess the global axial spondyloarthritis market by focusing on the marketed and potential pipeline therapies catering to ankylosing spondylitis and non-radiographic axial spondyloarthritis. The current market for axial spondyloarthritis is majorly dominated by the pharmaceutical companies such as AbbVie Inc., Amgen Inc., Pfizer Inc., Johnson & Johnson Services, Inc., and Novartis International AG.

The global axial spondyloarthritis market is expected to witness high growth, attributing to the growing prevalence of axial spondyloarthritis, favorable regulatory environment, and increase in adoption of biological agents in the field of axial spondyloarthritis. The continued significant investments by the emerging and legacy companies to meet industry demand and the growing adoption of novel therapeutics by the rheumatologists are the major factors propelling the growth of the global axial spondyloarthritis market.

The preceding figure represents the global axial spondyloarthritis market from 2021 to 2032. The market size in 2021 was $1,873.8 million and is expected to reach $7,954.9 million in 2032, growing at a CAGR of 13.44% during the forecast period, 2022-2032.

Comments

Post a Comment

Popular posts from this blog

Chatbots Increasing Efficiency in Healthcare Market

Chatbots are one of the prominent technologies currently being integrated into the healthcare system. The chatbots are not considered as the SaMD (software as medical device) as they do not participate in clinical decision-making process, rather, they act as the personal healthcare assistant as well as the trainer for its users. Click Here To Get Detailed Description of  Chatbots in Healthcare Market The usage of chatbots in the healthcare has gained popularity since 2013, when Babylon Health, the first healthcare chatbot company of the U.K. was launched. The company offered symptom checker chatbot and has started using the same chatbot as a health checker as well. The industry comprises the bot developers, platform providers, content providers, and the interface providers. Since there are no regulatory bodies such as FDA and MHRA directly governing the usage of chatbots, launching the chatbot is convenient for the developers. New start-ups are coming up wit...
2 comments
Read more

Wireless Charging Technology – Analyzing the Market Drivers and Restraints

Wireless charging technology eliminates the use of wires to power devices and enables a device to be charged automatically when placed near a transmitter. The wireless charging technology is however, not new in the world of technology, rather, has been in existence since the late 1800s. With the incorporation of the technology in smartphones, it has been experiencing a massive boost in popularity. Request the Sample @  https://bisresearch.com/requestsample?id=645&type=download According to the latest market intelligence report by BIS Research titled “ Global Wireless Charging Market - Analysis and Forecast (2018-2023) ,” the market was valued at $2.58 billion in 2017 and is projected to grow at a CAGR of 40.97%, during the forecast period and reach $20.97 billion by 2023.  The market is estimated to witness the highest growth in the Asia-Pacific (APAC) region during the forecast period (2018-2023). The wireless charging technology is not only limited to the sm...
1 comment
Read more

Neoantigens Vaccines Can Bridge the Treatment Gap by Training the Immune System to Recognize Tumor Cells

As per BIS Research analysis, the neoantigen cancer vaccine market is projected to reach $1826.1 million by 2030 from $227.1 million in 2023, at a CAGR of 34.69%. Growth in this market is expected to be driven by the ever-rising patient pool of different cancers and significant investment in research for development for cancer neoantigen vaccines to fill in the current treatment gaps. However, there are significant challenges that are restraining the market growth. These challenges include the high cost of therapy (personalized cancer vaccines), manufacturing complications, and lack of therapeutic biomarkers and assays. The market is still at the nascent phase with more than two-thirds of the neovaccines in the early stages of development. However, few neovaccines companies such as OSE Immunotherapeutics, Immunovative Therapeutics, Medigene, and Roche have positioned themselves to launch their neovaccines in the market within the upcoming years. That being said, the neovacc...
1 comment
Read more